No Data
No Data
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Foghorn Therapeutics Raises ~$110 Million Through Direct Offering
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Express News | Foghorn Therapeutics Inc.: Extends Cash Runway Into 2027